Annovis Bio prices $21 million stock and warrant offering amid NYSE deficiency

Annovis Bio, Inc. filed a final prospectus supplement dated November 5, 2026 for an offering of 19,000,000 shares of common stock with accompanying warrants to purchase up to 19,000,000 shares, plus pre-funded warrants to purchase up to 2,000,000 additional shares with accompanying warrants¹. The offering, underwritten by Canaccord Genuity, is priced at a combined public offering price of $1.00 per share and accompanying warrant¹. The warrants carry a five-year term from issuance and an exercise price of $1.00 per share¹.

The company said total offering proceeds before expenses and fees were expected at $19,797,300, on a total offering price of $20,999,800¹. One of the company's directors agreed to participate, with that director committing to purchase 5,000,000 shares of common stock and accompanying warrants for approximately $5,000,000¹, at the same price as other investors.

Annovis common stock trades on the NYSE under "ANVS" and closed at $1.09 per share on November 3, 2026¹. The company previously disclosed that on October 29, 2026, it received notice from the NYSE that it fell out of compliance with continued listing standards because its 30 trading-day average market capitalization and stockholders' equity were both below $50 million¹, with the deficiency figures at approximately $48.4 million in average market cap and a stockholders' deficit of approximately $(4.3) million as of June 30, 2026¹.

On cash, Annovis estimated its cash at approximately $2,819,898 as of September 30, 2026¹. Net proceeds, estimated at approximately $19.6 million after underwriting discounts, commissions and expenses¹, will go toward continued clinical development of lead compound buntanetap and for working capital and general corporate purposes¹.

The company's pivotal Phase 3 trial in early Alzheimer's disease (NCT06709014) reached full enrollment as announced on July 7, 2026¹, with 850 patients enrolled with pTau217-confirmed AD pathology across 83 clinical sites in the US¹. Delivery of the new securities was expected on or about November 6, 2026¹.